Westfield, NJ, United States of America

John F Cline


Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 67(Granted Patents)


Company Filing History:


Years Active: 1995-2002

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of John F. Cline

Introduction

John F. Cline is a notable inventor based in Westfield, NJ (US), recognized for his significant contributions to the field of controlled release devices. With a total of two patents to his name, Cline has made strides in the development of innovative methods that enhance drug delivery systems.

Latest Patents

Cline's latest patents include a method for injection molding manufacture of controlled release devices. This invention involves the production of thermoset polymer controlled release devices through the injection molding of two or more polymers in a mold, resulting in a core surrounded by a sheath. The polymers can be injected either sequentially or simultaneously. Another significant patent focuses on the transdermal administration of amines with minimal irritation. This patent describes an effective method for administering a skin irritating physiologically active amine in a minimally or nonirritating composition, which maintains a suitably high transdermal flux rate by utilizing a minimally or nonirritating salt of a fatty acid in a nonpolar, nonvolatile solvent.

Career Highlights

Throughout his career, John F. Cline has worked with several companies, including Enhance Pharmaceuticals, Inc. and Purepac, Inc. His work in these organizations has contributed to advancements in pharmaceutical technologies and drug delivery systems.

Collaborations

Cline has collaborated with notable coworkers such as Michelle McKenna and Angela Reid-Haqq, further enhancing the innovative environment in which he operates.

Conclusion

John F. Cline's contributions to the field of controlled release devices and drug delivery systems highlight his role as a significant inventor. His innovative patents and collaborations reflect his commitment to advancing pharmaceutical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…